While they may not have control over how drug manufacturers choose to communicate risks, patients can proactively discuss potential side effects with their doctors
The SELECT trial showed cardiovascular benefit for semaglutide in a different population (obesity without diabetes), but whether semaglutide's modest advantage over dulaglutide in glycaemic control translates to a meaningful difference in hard endpoints for type-2 diabetes patients remains an open question
doi: 10.1152/ajpregu.1984.246.5.R776 58 EidenSDanielCSteinbrueckASchmidtISimonE
This keeps the process smooth and gentle on your veins
Methylene blue and its potential in the treatment of traumatic brain injury, brain ischemia, and Alzheimers disease
Were happy to hype GLP-1s because diet, education, exercise programs, etc